[Skip to Navigation]
Article
February 1960

Drug Therapy in Schizophrenia: A Controlled Study of the Relative Effectiveness of Chlorpromazine, Promazine, Phenobarbital, and Placebo

Author Affiliations

Washington, D.C.; Palo Alto, Calif.; Perry Point, Md.
From the Veterans Administration Cooperative Studies of Chemotherapy in Psychiatry. The presented authorship indicates only major roles in coordinating the study and preparing this report. Other major contributors to this study were Thomas G. Andrews, Ph.D.; Eugene Caffey Jr., M.D.; S. T. Ginsberg, M.D.; Joseph Cameron, M.A., Amedeo S. Marrazzi, M.D., and Marcus P. Rosenblum, M.D. Additional participants, numbering several hundred, have been acknowledged in the Transactions of the First (1956), Second (1957), and Third (1958) Research Conferences on Chemotherapy in Psychiatry, published by the U.S. Veterans Administration Department of Medicine and Surgery, Washington 25, D.C.
Director, Psychiatry and Neurology Service, Department of Medicine and Surgery, Veterans Administration Central Office, Washington, D.C. (Dr. Casey). Chief, Psychiatric Research, Psychiatry and Neurology Service, Department of Medicine and Surgery, Veterans Administration Central Office; now with Eli Lilly & Company (Dr. Bennett). Special Assistant to Director, Psychiatry and Neurology Service, Department of Medicine and Surgery, Veterans Administration Central Office, Washington, D.C. (Mr. Lindley). Chief, Medical Service, Veterans Administration Hospital, Palo Alto, Calif. (Dr. Hollister). Assistant Chief, Central Neuropsychiatric Research Laboratory, Veterans Administration Hospital, Perry Point, Md.; now with National Institute of Neurological Diseases and Blindness, National Institutes of Health, U.S. Public Health Service, Department of Health, Education, and Welfare (Dr. Gordon). Chief, Central Neuropsychiatric Research Laboratory, Veterans Hospital, Perry Point, Md.; now Area Chief Clinical Psychologist, Office of the Area Medical Director, Veterans Administration, Trenton, N.J. (Dr. Springer).

AMA Arch Gen Psychiatry. 1960;2(2):210-220. doi:10.1001/archpsyc.1960.03590080086012
Abstract

Despite the vast number of clinical investigations of tranquilizing agents which followed their introduction, relatively few studies have used adequate controls. Such controlled studies as were done often were based on small numbers of patients, involved differing control techniques, or led to contradictory conclusions.1-6

Because of the difficulty in obtaining controlled drug studies of sufficient scope to be clinically meaningful, a cooperative study was planned to include psychiatric hospitals in the Veterans Administration nation-wide system. Such a study had the advantage of including a large and well-defined sample of patients treated in multiple hospital settings. Difficulties, anticipated in establishing a commonly understood research protocol and obtaining evaluations of treatment sufficiently similar to permit pooling of the data, did not prove to be insurmountable.

At the time this study was planned, two trends were already evident in regard to tranquilizing drugs.7 One was that reserpine

Add or change institution
×